Development of SARA(home), a new video-based tool for the assessment of ataxia at home by Grobe-Einsler, M. et al.
with breast cancer: a case–control study in Taiwan. European Jour-
nal of Clinical Pharmacology 2018;74:99–107.
26. Montastruc F, Khosrow-Khavar F, de Germay S, et al. Tamoxifen
and the risk of parkinsonism: a case/non-case study. Eur J Clin
Pharmacol 2018;74:1181–1184.
27. Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caf-
feine consumption and risk of Parkinson’s disease in men and
women. Ann Neurol 2001;50:56–63.
28. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia
nigra regional selectivity. Brain 1991;114(Pt 5):2283–2301.
29. Agalliu I, San Luciano M, Mirelman A, et al. Higher frequency of
certain cancers in LRRK2 G2019S mutation carriers with Parkinson
disease: a pooled analysis. JAMA Neurol 2015;72:58–65.
30. Warø BJ, Aasly JO. Exploring cancer in LRRK2 mutation carriers
and idiopathic Parkinson’s disease. Brain Behav 2017;8:e00858-e.
Development of SARAhome, a New
Video-Based Tool for the
Assessment of Ataxia at Home
Marcus Grobe-Einsler, MD,1,2* Arian Taheri Amin,1,2
Jennifer Faber, MD,1,2 Tamara Schaprian, PhD,1
Heike Jacobi, MD,1,3 Tanja Schmitz-Hübsch, MD,4
Alhassane Diallo, PhD,5,6
Sophie Tezenas du Montcel, PhD,7 and
Thomas Klockgether, MD1,2
1German Center for Neurodegenerative Diseases (DZNE), Bonn,
Germany 2Department of Neurology, University Hospital Bonn,
Bonn, Germany 3Department of Neurology, University Hospital of
Heidelberg, Heidelberg, Germany 4Experimental and Clinical
Research Center, A Cooperation of Charité – Universitätsmedizin
Berlin and Max-Delbrueck Center for Molecular Medicine, Berlin,
Germany 5INSERM U1137-IAME, Department of Biostatistical
Modeling, Clinical Investigation, Pharmacometrics in Infectious
Diseases, University Paris Diderot, Paris, France 6Department of
Epidemiology, Biostatistics and Clinical Research, APHP Bichât-
Claude-Bernard Hospital, Paris, France 7Sorbonne Université,
Institut, Pierre Louis d’Epidémiologie et de Santé Publique,
Assistance Publique-Hôpitaux de Paris, Institut National de la Santé
et de la Recherche Médicale, University Hospital Pitié-Salpêtrière,
Paris, France
ABSTRACT: Background: Clinical scales such
as the Scale for the Assessment and Rating of Ataxia
(SARA) cannot be used to study ataxia at home or to
assess daily fluctuations. The objective of the current
study was to develop a video-based instrument, SAR-
Ahome, for measuring ataxia severity easily and inde-
pendently at home.
Methods: Based on feasibility of self-application, we
selected 5 SARA items (gait, stance, speech, nose-
finger test, fast alternating hand movements) for SAR-
Ahome (range, 0–28). We compared SARAhome items
with total SARA scores in 526 patients with spi-
nocerebellar ataxia types 1, 2, 3, and 6 from the
EUROSCA natural history study. To prospectively vali-
date the SARAhome, we directly compared the self-
applied SARAhome and the conventional SARA in 50
ataxia patients. To demonstrate feasibility of indepen-
dent home recordings in a pilot study, 12 ataxia
patients were instructed to obtain a video each morn-
ing and evening over a period of 14 days. All videos
were rated offline by a trained rater.
Results: SARAhome extracted from the EUROSCA
baseline data was highly correlated with conventional
SARA (r = 0.9854, P < 0.0001). In the prospective vali-
dation study, the SARAhome was highly correlated with
the conventional SARA (r = 0.9254, P < 0.0001). Five
of 12 participants of the pilot study obtained a com-
plete set of 28 evaluable videos. Seven participants
obtained 13–27 videos. The intraindividual differences
between the lowest and highest SARAhome scores
ranged from 1 to 5.5.
Conclusion: The SARAhome and the conventional
SARA are highly correlated. Application at home is
feasible. There was a considerable degree of intra-
individual variability of the SARAhome scores. © 2021
The Authors. Movement Disorders published by Wiley
Periodicals LLC on behalf of International Parkinson
and Movement Disorder Society.
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Ataxias refer to a group of degenerative diseases of
the nervous system in which progressive ataxia is the
core feature of clinical manifestation. They comprise
diseases of both genetic and nongenetic origin. In most
of them, there is prominent damage of the cerebellar
cortex with consecutive cerebellar atrophy, but other
parts of the nervous system, such as the spinal cord,
basal ganglia, brain stem, and peripheral nerves, can be
involved.
Proper assessment of the severity of ataxia is essential
for clinical care, but even more for observational stud-
ies and interventional trials. This is done using clinical
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scales, such as the Scale for the Assessment and Rating
of Ataxia (SARA), an extensively validated scale that is
applied by trained examiners in a clinical or research
environment.1 Such scales cannot be used to study the
severity of ataxia at home or to assess day-to-day and
within-day fluctuations, which are reported by almost
all ataxia patients. It is therefore important to develop
new instruments based on digital technology that allow
measuring severity of ataxia at home.2,3 Digital technol-
ogies are providing new opportunities for this purpose.
The urgent need for instruments that allow remote
assessment of ataxia is underlined by the current
COVID-19 pandemic that impeded patient care and led
to interruption of observational and interventional tri-
als in ataxia.
We here present a video-based assessment, SAR-
Ahome, that can be easily done independently of the




Based on a detailed analysis of the feasibility of self-
application at home, we selected 5 of the 8 SARA
items (gait, stance, speech, nose-finger test, fast alter-
nating hand movements) for SARAhome. The SAR-
Ahome sum score ranges from 0 to 28, with
0 indicating absence of ataxia and 28 being the most
severe degree of ataxia. To facilitate implementation,
we made small changes to the instructions including
reduction of the walking distance to 5 m (1 way), per-
formance of fast-alternating hand movements and
nose-finger test on a chair allowing support of the feet
for every patient and replacement of the investigator’s
finger that serves as the target in the nose-finger test
by a tape-mark on the wall (Fig. 1). After instruction
by an experienced rater, patients performed SARAhome
without further assistance in front of a tablet camera.
Severely affected patients were allowed support by a
second person during gait and stance, in analogy to
conventional SARA. If an item could not be per-
formed, patients were asked to verbally share that
information on video to be used for rating. SARAhome
was performed in the hospital during the validation
study and at home during the pilot study. The tablets
were supplied by the study-site for the duration of the
study and returned after the last recording for down-
load and rating of videos.
Study Participants
To compare the results of the 5 SARA items selected
for SARAhome with those of the complete SARA, we
retrospectively analyzed the baseline data of
526 patients with spinocerebellar ataxia types 1, 2,
3, and 6 from the EUROSCA natural history study.4,5
To calculate progression and performance over time,
we analyzed an additional 415 SARA scores from
follow-up after 1 year, 416 after 2 years, and 336 after
3 years. To prospectively validate SARAhome, we
directly compared the results of SARAhome with those
of conventional complete SARA in 50 ataxia patients.
To demonstrate feasibility of independent home record-
ings, we performed a pilot study in 12 patients. Inclu-
sion criteria in both studies were clinical diagnosis of
cerebellar ataxia and capability to comply with study
protocol. Study participants of the prospective valida-
tion study and the pilot study were consecutively rec-
ruited from ongoing ataxia studies of the German
Center for Neurodegenerative Diseases (DZNE), 4
patients from the prospective validation also partici-
pated in the pilot study. Patient characteristics are given
in Table 1. All studies were approved by the responsible
ethics committee. Written informed consent was
obtained from all study participants at enrollment.
Prospective Validation Study
The prospective validation study was performed in
the DZNE clinical trial unit in Bonn, Germany. The
SARA score was obtained from all study participants
by a trained and experienced examiner. Subsequently,
study participants received oral instructions on how to
perform SARAhome. Subjects then performed SARAhome
independently without any further assistance using a
tablet device. Only subjects at risk of falling received
support, if necessary. Videos were rated by a trained
and experienced rater (T.K.) who had no knowledge of
the conventional SARA score.
Pilot Study
To demonstrate feasibility under real-life conditions
at home and collect first data about daily fluctuation
and training effects, 12 ataxia patients performed SAR-
Ahome twice daily (morning and evening) for a period of
14 days in a pilot study. Initial instructions were given
by a trained investigator either during a study visit
(n = 7) or via a video call (n = 5). Therefore, baseline
SARA was not always available in the pilot study. In
addition, subjects received detailed instructions for each
item via a printout or digitally presented on the tablet
device supplied by the DZNE that was also used to
record SARAhome performance on video (Fig. S1). All
videos of the pilot study were rated by an experienced
rater (M.G.E.).
Statistical Analysis
A linear model was used to compare SARA and SAR-
Ahome items in the retrospective and prospective analy-
sis, and Pearson’s correlation was calculated. To see if
the differences in the scores of single items were similar
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across the spectrum of severity, we performed a Bland–
Altman analysis of the respective 5 items of SARA with
SARAhome scores from the prospective validation study.
To calculate progression and performance over time
between SARA and SARAhome (retrospective data), a
bivariate linear mixed model was used. In the pilot
study, a 2-way repeated-measures analysis of variance
was performed to evaluate the effect of different times
(morning/evening) and day of assessment on SARAhome
score. To determine how many recording days are
required to obtain a representative estimate of the entire
14-day period, we calculated mean values and
confidence intervals for cumulative days. All analyses
were done using GraphPad Prism version 7.02 and R
versions 3.4.3. and 3.5.1.
Results
The SARAhome score extracted from the EUROSCA
baseline data was highly correlated with the SARA
score (r = 0.985, P < 0.0001; Fig. S2a). Progression of
SARAhome and SARA were also highly correlated
(r = 0.935, P < 0.0001).
FIG. 1. SARAhome setup. (A) Gait is performed on a 5-m walkway in front of the tablet or smartphone placed on a tripod. Marks on the floor indicate
position of the tripod (0 m), 2- and 5-m distances. Patient walks back and forth, as indicated by the dashed line (1). Subsequently, the patient walks
from the 5-m mark toward the camera in tandem (2). (B) Stance is performed on the 2-m mark at a 45o angle to the camera. If practicable, 3-foot posi-
tions are taken (1-3). (C) Fast alternating hand movements and speech are performed sitting on a chair at the 2-m position in front of the camera.
(D) Nose-finger test is performed sitting on a chair at the 2-m position that is rotated by 90o so that the patient faces the wall. Pointing movements are
performed toward a mark attached to the wall at eye height.
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In the prospective validation study, no falls or injuries
occurred during testing. The SARAhome score derived
from video rating was highly correlated with the con-
ventional complete SARA score (r = 0.9254, P <
0.0001; Fig. S2b). Item-specific analysis showed corre-
lation coefficients ranging from 0.7594 for fast alternat-
ing hand movements to 0.9433 with P < 0.0001 for
gait (Table S1). Bias of Bland–Altman analysis was
0.76, and >95% of all data points lay within the 95%
limits of agreement, suggesting that SARA and SAR-
Ahome are similar across the entire spectrum of severity
(Fig. S3).
Five of 12 participants obtained a complete set of
28 recordings, and 7 participants obtained at least
1 recording per day. A comprehensive list of available
recordings is given in Table S2. In total, 7 of
293 recordings were rated as missing because of incor-
rect performance of single items (stance, 2; alternating
hand movements, 5). There were no falls or injuries
during the home recordings. The intraindividual differ-
ences between the lowest and highest SARAhome score
ranged from 1 to 5.5 (mean ± SD, 3.3 ± 1.3; see
Fig. S4). The time of assessment (morning vs evening)
had no statistically significant effect on SARAhome score
(F 1,4 = 1.435, P = 0.297), and there was no significant
training effect during the 14 days of assessments
(F13,52 = 1.234, P = 0.238). Interaction between these
terms was also not statistically significant
(F13,52 = 0.881, P = 0.577; Table S3). The width of
confidence intervals of SARAhome scores dropped from
4.77 for 1-day to 1.25 for 14-day recordings. For all
recording periods longer than 3 days, confidence inter-
vals were less than twice the 14-day value (Fig. S5).
Discussion
We have developed and validated a video-based
assessment of ataxia, SARAhome, that is derived from
the original SARA and can be self-applied by patients
at home. A retrospective analysis of data from the
EUROSCA natural history study and a prospective
validation study performed in 50 ataxia patients
showed high correlations between SARAhome and con-
ventional SARA and similarity of both scales across
the spectrum of severity. We further demonstrated the
feasibility of home recordings in a pilot study in
12 ataxia patients.
There have been several attempts to develop digital
ataxia assessment tools, which are applicable to home
testing.6-10 Some of these approaches focused on single
SARA items,6-8 whereas others introduced items that
are not included in SARA.8-10 One example is a tool
that uses commercially available devices from video
games (Microsoft Kinect, Leap Motion Controller)
together with a computer screen to record performance
of pediatric ataxia patients in 6 of 8 SARA items.10
Other instruments relied on accelerometers.6,8 Real
data from home recordings with any of these tools have
not been published.
SARAhome has the principal advantage that it is
completely video-based without the need for specific
hardware or an examiner. SARAhome can be performed
with any tablet or smartphone that possesses a camera.
In collaboration with a commercial partner, we have
developed an app that patients can download on their
own devices. The app provides detailed instructions for
users and enables recording as well as secure transfer of
SARAhome video recordings for off-line rating. As SAR-
Ahome is directly derived from SARA, and SARAhome
and SARA scores are highly correlated, SARAhome may
partly substitute for a conventional SARA assessment
in hospitals or research institutions, for example,
between scheduled study visits or in situations, such as
the COVID-19 pandemic, in which hospital visits are
not possible. Currently, SARAhome is still dependent on
off-line rating by a trained rater, which eliminates inter-
rater variability. Intrarater reliability has not been
explored in this study, but we expect similar results as
those for SARA. In the future, subjective rating may be
replaced by automatic video tracking.
Our pilot study in a small group of ataxia patients
demonstrated that SARAhome can be safely and reliably
performed by patients independently at home.
TABLE 1. Characteristics of patients of the validation and
pilot studies
Validation
study (n = 50)
Pilot
study (n = 12)
SCA1 (n) 2 4
SCA2 (n) 2 0
SCA3 (n) 12 3
SCA6 (n) 6 0
MSA-C (n) 7 2
Recessive ataxia (n) 11 0
Friedreich (n) 2 1
Others (n) 8 2










SARA, mean ± SD (range) 14.2 ± 7.2
(0–32)
Not availablea
SARAhome, mean ± SD (range) 9.3 ± 6.0 (0–25) 7.5 ± 5.0
(0.1–17.8)b
Age, disease duration, and SARA score are shown as mean ± standard devi-
ation (range).
aBaseline SARA was not available for all participants because 5 of the 12
patients in the pilot study had no study visit in the hospital and received only
online instructions.
bMean SARAhome from all available recordings.
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However, a possible limitation is the applicability in
very severely affected patients and patients with
major cognitive impairment who may need supervi-
sion. For the first time, this study provided data on
fluctuation of ataxia severity. Fluctuations of the
SARAhome score of at least 1 point were observed in
all patients. However, we detected neither systematic
differences of ataxia severity between morning and
evening nor a training effect. To fully determine the
causes of fluctuations, larger trials are required. Based
on the analysis of confidence intervals for cumulative
days, we suggest that a recording period of 4 days is
representative for the entire 14-day period and pro-
vides a more meaningful measure of ataxia severity
than a single conventional SARA assessment in the
hospital.
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ABSTRACT: Background: The pathophysiology
of cervical dystonia is still unclear. Recent evidence
points toward a network disorder affecting several
brain areas. The objective of this study was to assess
the saccadic inhibition as a marker of corticostriatal
function in cervical dystonia.
Methods: We recruited 31 cervical dystonia patients
and 17 matched healthy controls. Subjects performed
an overlap prosaccade, an antisaccade, and a cou-
ntermanding task on an eye tracker to assess auto-
matic visual response and response inhibition.
Results: Cervical dystonia patients made more pre-
mature saccades (P = 0.041) in the overlap pro-
saccade task and more directional errors in the
antisaccade task (P = 0.011) and had a higher rate of
failed inhibition in the countermanding task
(P = 0.001).
Conclusions: The results suggest altered saccadic
inhibition in cervical dystonia, possibly as a conse-
quence of dysfunctional corticostriatal networks. Fur-
ther studies are warranted to confirm whether these
abnormalities are affected by the available therapies
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